Screener
Denali Therapeutics Inc. DNLI Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Denali Therapeutics Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:08 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001714899-26-000097
| Line item | As of / June 30, 2026 | As of / December 31, 2025 |
|---|---|---|
| Accrued compensation | $13,424 | $32,179 |
| Accrued clinical and other research & development costs | 19,871 | 22,283 |
| Accrued manufacturing costs | 10,659 | 5,336 |
| Operating lease liability, current | 10,084 | 9,463 |
| Finance lease liability, current | 97 | 83 |
| Deferred research and development funding liability, current | 19,975 | 21,101 |
| Other accrued costs and current liabilities | 4,166 | 7,401 |
| Total accrued expenses and other current liabilities | $78,276 | $97,846 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Denali Therapeutics Inc.'s current debt?
- Denali Therapeutics Inc. (DNLI) reported current debt of $97K in Q2 2026.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Denali Therapeutics Inc.'s current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude